Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VNRX Volitionrx Ltd
- Stocks
- Healthcare
- NYSEAMERICAN: VNRX
Price (delayed)
$0.4299
Market cap
$41.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.31
Enterprise value
$44.06M
Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to
Highlights
The company's EPS rose by 38% YoY and by 14% QoQ
Volitionrx's net income has increased by 24% YoY and by 10% from the previous quarter
The quick ratio has soared by 126% from the previous quarter but it has plunged by 82% YoY
The gross profit has soared by 59% YoY but it has decreased by 4.1% QoQ
The equity is down by 16% since the previous quarter
Key stats
What are the main financial stats of VNRX
Market
Valuations
Earnings
Shares outstanding
96.54M
Market cap
$41.5M
Enterprise value
$44.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
30.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.72
Revenue
$1.23M
Gross profit
$1.23M
Operating income
-$27.02M
Net income
-$26.97M
EBIT
-$26.63M
EBITDA
-$25.29M
Free cash flow
-$26.17M
Per share
Balance sheet
Liquidity
EPS
-$0.31
EPS diluted
-$0.31
Free cash flow per share
-$0.3
Book value per share
-$0.27
Revenue per share
$0.01
TBVPS
$0.11
Total assets
$9.4M
Total liabilities
$35.51M
Debt
$5.82M
Equity
-$24.91M
Working capital
-$3.73M
Debt to equity
-0.23
Current ratio
0.52
Quick ratio
0.43
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
-2,050.1%
Gross margin
100%
Net margin
-2,186.3%
Operating margin
-2,190.9%
Return on assets
-197.6%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-1,655.1%
Return on sales
-2,158.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VNRX stock price
How has the Volitionrx stock price performed over time
Intraday
-5.22%
1 week
-14.02%
1 month
-14.02%
1 year
-46.26%
YTD
-28.35%
QTD
-24.59%
Financial performance
How have Volitionrx's revenue and profit performed over time
Revenue
$1.23M
Gross profit
$1.23M
Operating income
-$27.02M
Net income
-$26.97M
Gross margin
100%
Net margin
-2,186.3%
The gross profit has soared by 59% YoY but it has decreased by 4.1% QoQ
The revenue has surged by 59% year-on-year but it has declined by 4.1% since the previous quarter
The company's operating margin has surged by 53% YoY and by 6% QoQ
VNRX's net margin has soared by 52% YoY and by 6% QoQ
Price vs fundamentals
How does VNRX's price correlate with its fundamentals
Growth
What is Volitionrx's growth rate over time
Valuation
What is Volitionrx stock price valuation
P/E
N/A
P/B
N/A
P/S
30.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.72
The company's EPS rose by 38% YoY and by 14% QoQ
The equity is down by 16% since the previous quarter
The stock's P/S is 99% below its 5-year quarterly average of 3127.8 and 43% below its last 4 quarters average of 53.1
The revenue has surged by 59% year-on-year but it has declined by 4.1% since the previous quarter
Efficiency
How efficient is Volitionrx business performance
The company's return on sales has surged by 52% YoY and by 6% QoQ
Volitionrx's ROA has decreased by 28% YoY and by 21% from the previous quarter
Dividends
What is VNRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VNRX.
Financial health
How did Volitionrx financials performed over time
The company's total assets is 74% lower than its total liabilities
VNRX's current ratio has soared by 136% since the previous quarter but it has dropped by 79% year-on-year
The quick ratio has soared by 126% from the previous quarter but it has plunged by 82% YoY
VNRX's debt is 123% higher than its equity
The company's debt to equity has surged by 69% YoY and by 15% QoQ
The equity is down by 16% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.